	US 11,732,043 B2
	Antibodies that modulate a biological activity expressed by a cell
Cecilia Anna Wilhelmina Geuijen, Utrecht (NL); Rinse Klooster, Utrecht (NL); Cornelis Adriaan De Kruif, Utrecht (NL); Paulus Johannes Tacken, Utrecht (NL); Mark Throsby, Utrecht (NL); and Ton Logtenberg, Utrecht (NL)
Assigned to MERUS N.V., Utrecht (NL)
Appl. No. 16/628,939
Filed by Merus N.V., Utrecht (NL)
PCT Filed Jul. 6, 2018, PCT No. PCT/NL2018/050451 § 371(c)(1), (2) Date Jan. 6, 2020, PCT Pub. No. WO2019/009728, PCT Pub. Date Jan. 10, 2019.
Claims priority of application No. 17180070 (EP), filed on Jul. 6, 2017.
Prior Publication US 2020/0216540 A1, Jul. 9, 2020
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2818 (2013.01) [C07K 2317/31 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)]

22 Claims

1. An antibody or variant thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3;

wherein the variable domain that can bind to an extracellular part of PD-1 blocks the binding of PD-1 to PD-L1 and/or PD-L2; and

wherein the variable domain that can bind to an extracellular part of LAG3 comprises a heavy chain variable region with a CDR1, CDR2 and CDR3 region that comprises the amino acid sequence of the CDR1, CDR2 and CDR3 of a heavy chain variable region according to any one of SEQ ID NO: 58-81.